CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 15 enrolled
Drug / intervention
atorvastatindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05488067
NCT05488067Phase 4Completed
CompareCT.gov

The Safety and Efficacy of Atorvastatin on Xanthoma in Alagille Syndrome

Children's Hospital of Fudan University·interventional·Posted Aug 4, 2022·Updated Mar 27, 2026

In Brief

A Phase 4 clinical trial evaluating atorvastatin for Alagille Syndrome and 2 related conditions. Completed, enrolled 15 participants across 1 site.

Detailed Summary

To observe the efficacy and safety of atorvastatin on xanthoma in Alagille syndrome through a prospective study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlagille Syndrome, Atorvastatin, Xanthoma
CountriesChina
Collaborators--

Timeline

Phase 4CompletedFinished
2023202420252026
First PostedAug 4, 2022
Enrollment StartMar 22, 2022
Primary CompletionAug 1, 2024
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 3.9 years ago

Interventions

atorvastatindrug

Oral atorvastatin treatment for ALGS children with xanthoma